Valuation: ValiRx plc

Market Cap 1.78M 2.36M 2.07M 1.95M 3.33M 226M 3.36M 23.42M 9.08M 115M 8.87M 8.68M 374M P/E 2024
-0.53x
P/E 2025 -0.62x
Enterprise Value 992K 1.32M 1.15M 1.09M 1.85M 126M 1.87M 13.04M 5.05M 64.24M 4.94M 4.83M 208M EV / Sales 2024
27,264,249x
EV / Sales 2025 54,121,446x
Free-Float
99%
Yield 2024 *
-
Yield 2025 -
1 day-3.70%
1 week-10.34%
Current month-16.13%
1 month-16.13%
3 months-25.71%
6 months-55.93%
Current year-61.19%
1 week 0.13
Extreme 0.13
0.15
1 month 0.13
Extreme 0.13
0.16
Current year 0.13
Extreme 0.13
0.48
1 year 0.13
Extreme 0.13
0.65
3 years 0.13
Extreme 0.13
15
5 years 0.13
Extreme 0.13
65
10 years 0.13
Extreme 0.13
1,436.25
Manager TitleAgeSince
Chief Executive Officer 55 12/08/2024
Director of Finance/CFO 81 -
Chief Tech/Sci/R&D Officer - 27/03/2025
Director TitleAgeSince
Director/Board Member 81 01/09/2006
Chairman 60 25/07/2024
Director/Board Member 55 12/08/2024
Date Insider Type Main position Quantity % Market Cap. Importance
4/3/26 Buy

Chief Executive Officer

1,000,000 0.1346%
18/10/22 Free

Director

75,000 0.0832%
18/10/22 Free

Director

75,000 0.0832%
Change 5-day change 1-year change 3-year change Capi.($)
-3.70%-10.34%-79.20%-97.92% 2.38M
+0.06%+7.20%+54.04%+111.13% 74.27B
-2.29%-1.51%+33.30%+75.15% 61.21B
+0.28%+7.27%+31.74%+23.80% 27.55B
-1.42%-3.36%-18.52%+359.50% 26.38B
-1.83%+3.23%+0.67%-4.07% 25.34B
+0.57%+3.66%+25.59%-9.08% 20.84B
-1.47%+4.46%-8.09%+513.33% 14.94B
+1.29%-2.49%+163.31%+333.06% 15.17B
-2.34%+0.04%+42.69%+160.22% 14.41B
Average -1.10%+2.19%+24.55%+146.51% 28.01B
Weighted average by Cap. -0.86%+3.08%+35.56%+134.70%

Financials

2024 2025
Net sales 0.05 0.07 0.06 0.05 0.09 6.32 0.09 0.65 0.25 3.22 0.25 0.24 10.45 0.03 0.04 0.04 0.03 0.06 3.98 0.06 0.41 0.16 2.03 0.16 0.15 6.59
Net income -1.92M -2.54M -2.23M -2.1M -3.58M -243M -3.61M -25.17M -9.76M -124M -9.54M -9.33M -402M -2.23M -2.96M -2.6M -2.44M -4.17M -283M -4.2M -29.33M -11.37M -145M -11.11M -10.87M -469M
Net Debt -1.54M -2.05M -1.8M -1.69M -2.89M -196M -2.91M -20.29M -7.86M -99.97M -7.69M -7.52M -324M -790K -1.05M -919K -864K -1.48M -100M -1.49M -10.38M -4.02M -51.16M -3.93M -3.85M -166M
Logo ValiRx plc
ValiRx Plc is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of science into impactful medicines to improve patient lives. The Company provides the scientific, financial, and commercial framework for enabling rapid translation of science into clinical development. The Company selects and incubates novel drug candidates and guides them through an optimized process of development, from pre-clinical studies to clinical and investor-ready assets. Its product pipeline includes VAL201, VAL301, CLX001 and BC201. VAL201 is a short peptide being studied for the treatment of prostate cancer. VAL201 can prevent cancerous cell proliferation (or growth) without interfering with other functions of the androgen receptor or SRC kinase. CLX001 is a peptide in nanoparticle formulation and is designed for precision destruction of cancer cells to avoid excessive side effects.
Employees
11
Date Price Change Volume
23/09/26 GBX 0.1300 -3.70% 4,096,960
22/09/26 GBX 0.1350 0.00% 1,002,959
21/09/26 GBX 0.1350 -3.57% 5,326,975
18/09/26 GBX 0.1400 0.00% 1,838,973
17/09/26 GBX 0.1400 -3.45% 9,541,460

Annual profits - Rate of surprise